Dang Luan Minh, Soo Kim Eun, Kim Kyeong Ok, Lee Yoo Jin, Bui Hoang Huu, Nguyen Chuong Dinh, Nguyen Chi Thi, Nguyen Nam Hoai, Nguyen Hien Thi-Thu, Dinh Nga Thi, Nguyen Lien Thi-Phuong, Vu Khien Van, Duong Minh Cuong
IBD Unit, Department of Gastroenterology University Medical Center Ho Chi Minh City Vietnam.
Department of Internal Medicine University of Medicine and Pharmacy at Ho Chi Minh City Ho Chi Minh city Vietnam.
JGH Open. 2025 Feb 17;9(2):e70106. doi: 10.1002/jgh3.70106. eCollection 2025 Feb.
BACKGROUND/AIMS: The differences in the clinical course of Crohn's disease (CD) and ulcerative colitis (UC) among Asian countries remain unknown. Thus, we compared the clinical characteristics, treatment, and one-year outcomes of newly diagnosed inflammatory bowel disease (IBD) patients between Vietnam and Korea.
A retrospective cohort study was conducted at seven tertiary hospitals in these countries between January 2020 and January 2021. Data on demographics, diseases, treatment, and outcomes during 1 year after diagnosis were collected.
Among 225 patients (60 from Vietnam and 165 from Korea), 140 and 85 were diagnosed with UC and CD, respectively. Severe activity ( < 0.01) and extensive colitis ( < 0.01) in UC, along with complicated behavior in CD ( < 0.01), were more frequently observed in Vietnamese patients compared to Korean patients. The proportion of UC patients using corticosteroids ( < 0.01), immunomodulators ( < 0.01), and biologics ( = 0.026) was significantly higher in Vietnam. In contrast, the proportion of UC patients using topical mesalamine ( < 0.01) was significantly higher in Korea. The intervals from CD diagnosis to biologic therapy initiation ( = 0.04), as well as from UC diagnosis to corticosteroid ( < 0.01), immunomodulator ( < 0.01), and biologic therapy ( < 0.01) commencement, were significantly shorter in Vietnamese patients compared to Korean patients. However, the proportions of endoscopic healing and complications at 1-year follow-up did not significantly differ between the countries ( > 0.05).
Although Vietnamese IBD patients had higher baseline clinical and phenotypic severity than their Korean counterparts, no significant differences in short-term outcomes were observed, potentially reflecting the impact of the higher rate and early biologic usage in Vietnamese patients.
背景/目的：亚洲国家中克罗恩病（CD）和溃疡性结肠炎（UC）临床病程的差异尚不清楚。因此，我们比较了越南和韩国新诊断的炎症性肠病（IBD）患者的临床特征、治疗情况及一年的预后。
于2020年1月至2021年1月在这些国家的七家三级医院进行了一项回顾性队列研究。收集了诊断后1年内的人口统计学、疾病、治疗及预后数据。
在225例患者中（60例来自越南，165例来自韩国），分别有140例和85例被诊断为UC和CD。与韩国患者相比，越南患者中UC的重度活动（P<0.01）和广泛性结肠炎（P<0.01）以及CD的复杂性病变行为（P<0.01）更为常见。越南使用皮质类固醇（P<0.01）、免疫调节剂（P<0.01）和生物制剂（P=0.026）的UC患者比例显著更高。相比之下，韩国使用局部美沙拉嗪的UC患者比例显著更高（P<0.01）。与韩国患者相比，越南患者从CD诊断到开始生物治疗的间隔时间（P=0.04）以及从UC诊断到开始使用皮质类固醇（P<0.01）、免疫调节剂（P<0.01）和生物治疗（P<0.01）的间隔时间显著更短。然而，两国在1年随访时的内镜愈合率和并发症比例没有显著差异（P>0.05）。
尽管越南IBD患者的基线临床和表型严重程度高于韩国患者，但短期预后没有显著差异，这可能反映了越南患者生物制剂使用率更高及使用更早的影响。
